Last reviewed · How we verify

Beta-3 Agonists, Adrenergic

Baylor Research Institute · FDA-approved active Small molecule Quality 5/100

Beta-3 Agonists, Adrenergic is a Small molecule drug developed by Baylor Research Institute. It is currently FDA-approved. Also known as: Mirabegron, Myrbetriq.

At a glance

Generic nameBeta-3 Agonists, Adrenergic
Also known asMirabegron, Myrbetriq
SponsorBaylor Research Institute
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Beta-3 Agonists, Adrenergic

What is Beta-3 Agonists, Adrenergic?

Beta-3 Agonists, Adrenergic is a Small molecule drug developed by Baylor Research Institute.

Who makes Beta-3 Agonists, Adrenergic?

Beta-3 Agonists, Adrenergic is developed and marketed by Baylor Research Institute (see full Baylor Research Institute pipeline at /company/baylor-research-institute).

Is Beta-3 Agonists, Adrenergic also known as anything else?

Beta-3 Agonists, Adrenergic is also known as Mirabegron, Myrbetriq.

What development phase is Beta-3 Agonists, Adrenergic in?

Beta-3 Agonists, Adrenergic is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing